The role of Tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor γ antagonism

Endocrinology

Volumn 150, Issue 1, 2009, Pages 104-113

  Gong, Zhenwei ^a   Huang, Cheng ^a   Sheng, Xiaoyan ^a   Zhang, Yuebo ^a   Li, Qunyi ^b   Wang, Ming Wei ^b   Peng, Linling ^c   Zang, Ying Qin ^a,d  

^a Graduate School   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c Shanghai Jiao Tong University Science and Education Plaza   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TANSHINONE IIA;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG ANTAGONISM; FAT BODY; FEMALE; FOOD INTAKE; GLUCOSE TOLERANCE; HEART PROTECTION; LIGAND BINDING; LIPID DIET; LIPOGENESIS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; TRANSCRIPTION INITIATION;

3T3 CELLS; ANIMALS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY WEIGHT; DNA, COMPLEMENTARY; FEMALE; FLOW CYTOMETRY; GENES, REPORTER; GLUCOSE TOLERANCE TEST; LIPIDS; MICE; MICE, INBRED C57BL; OBESITY; PHENANTHRENES; POLYMERASE CHAIN REACTION; PPAR GAMMA; RNA; TRANSFECTION;

EID: 58149471235     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0322     Document Type: Article

References (47)

1. Glass CK, Witztum JL 2001 Atherosclerosis. The road ahead. Cell 104: 503-516
2. Nawrocki AR, Scherer PE 2005 Keynote review: the adipocyte as a drug discovery target. Drug Discov Today 10:1219-1230
3. Evans RM, Barish GD, Wang YX 2004 PPARs and the complex journey to obesity. Nat Med 10:355-361
4. Pakala R, Rha SW, Kuchulakanti PK, Cheneau E, Baffour R, Waksman R 2004 Peroxisome proliferator-activated receptor γ; its role in atherosclerosis and restenosis. Cardiovasc Radiat Med 5:44-48
5. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM 1994 mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234
6. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM 1992 Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774
7. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM 1999 PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617
8. Hu E, Tontonoz P, Spiegelman BM 1995 Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR γ and C/EBP α. Proc Natl Acad Sci USA 92:9856-9860
9. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Mild H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T 2001 The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPAR γ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 276:41245-41254
10. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM 2000 A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation. J Biol Chem 275: 1873-1877
11. Nakano R, Kurosaki E, Yoshida S, Yokono M, Shimaya A, Maruyama T, Shibasaki M 2006 Antagonism of peroxisome proliferator-activated receptor γ prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol 72:42-52
12. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W 2002 A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16:2628-2644
13. Hazra B, Das Sarma M, Sanyal U 2004 Separation methods of quinonoid constituents of plants used in Oriental traditional medicines. J Chromatogr B Analyt Technol Biomed Life Sci 812:259-275
14. Hur JM, Shim JS, Jung HJ, Kwon HJ 2005 Cryptotanshinone but not tanshinone IIA inhibits angiogenesisin vitro. Exp Mol Med 37:133-137
15. Ji X, Tan BK, Zhu YC, Linz W, Zhu YZ 2003 Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats. Life Sci 73:1413-1426
16. Liu AH, Lin YH, Yang M, Sun JH, Guo H, Guo DA 2006 High-performance liquid chromatographic determination of tanshinones in the roots of Salvia miltiorrhiza and related traditional Chinese medicinal preparations. J Pharm Pharm Sci 9:1-9
17. Zhou G, Jiang W, Zhao Y, Ma G, Xin W, Yin J, Zhao B 2003 Sodium tanshin one IIA sulfonate mediates electron transfer reaction in rat heart mitochondria. Biochem Pharmacol 65:51-57
18. Ji XY, Tan BK, Zhu YZ 2000 Salvia miltiorrbiza and ischemic diseases. Acta Pharmacol Sin 21:1089-1094
19. Wang AM, Sha SH, Lesniak W, Schacht J 2003 Tanshinone (Salviae miltiorrbizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother 47:1836-1841
20. Il Jang S, Jin Kim H, Kim YJ, Jeong SI, You YO 2006 Tanshinone IIA inhibits LPS-induced NF-κB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p. 38 and JNK pathways. Eur J Pharmacol 542:1-7
21. Jang SI, Jeong SI, Kim KJ, Kim HJ, Yu HH, Park R, Kim HM, You YO 2003 Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-α, IL-1β and IL-6 in activated RAW 264.7 cells. Planta Med 69:1057-1059
22. Huang C, Zhang Y, Gong Z, Sheng X, Li Z, Zhang W, Qin Y 2006 Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway. Biochem Biophys Res Commun 348:571-578
23. Wu B, Gao J, Wang MW 2005 Development of a complex scintillation proximity assay for high-throughput screening of PPARγ modulators. Acta Pharmacol Sin 26:339-344
24. Cheng Y, Prusoff WH 1973 Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
25. Willcox BE, Gao GF, Wyer JR, Ladbury JE, Bell JI, Jakobsen BK, van der Merwe PA 1999 TCR binding to peptide-MHC stabilizes a flexible recognition interface. Immunity 10:357-365
26. Rangwala SM, Lazar MA 2000 Transcriptional control of adipogenesis. Annu Rev Nutr 20:535-559
27. Rosen ED, Spiegelman BM 2000 Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 16:145-171
28. Shearer BG, Billin AN 2007 The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 1771:1082-1093
29. Davidson F 1996 Hyperinsulinemia and the risk of coronary heart disease. N Engl J Med 335:976
30. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ 1996 Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957
31. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J 1997 The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272:18779-18789
32. Abella A, Dubus P, Malumbres M, Rane SG, Kiyokawa H, Sicard A, Vignon F, Langin D, Barbacid M, Fajas L 2005 Cdk4 promotes adipogenesis through PPARγ activation. Cell Metab 2:239-249
33. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-Deoxy-δ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell 83:803-812
34. Tontonoz P, Hu E, Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Cell 79: 1147-1156
35. Ye F, Zhang ZS, Luo HB, Shen JH, Chen KX, Shen X, Jiang HL 2006 The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARγ: bioassay with molecular modeling simulation. Chembiochem 7:74-82
36. Hajduch E, Litherland GJ, Hundal HS 2001 Protein kinase B (PKB/Akt) - a key regulator of glucose transport? FEBS Lett 492:199-203
37. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K, Miki H, Kubota N, Terauchi Y, Tsuchida A, Tsuboyama-Kasaoka N, Yamauchi N, Ide T, Hori W, Kato S, Fukayama M, Akanuma Y, Ezaki O, Itai A, Nagai R, Kimura S, Tobe K, Kagechika H, Shudo K, Kadowaki T 2001 Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013
38. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T 1999 PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609
39. Tiraby C, Langin D 2003 Conversion from white to brown adipocytes: a strategy for the control of fat mass? Trends Endocrinol Metab 14:439-441
40. Tiraby C, Tavernier G, Lefort C, Larrouy D, Bouillaud F, Ricquier D, Langin D 2003 Acquirement of brown fat cell features by human white adipocytes. J Biol Chem 278:33370-33376
41. Gao J, Yang G, Pi R, Li R, Wang P, Zhang H, Le K, Chen S, Liu P 2008 Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res 151:79-87
42. Fu J, Huang H, Liu J, Pi R, Chen J, Liu P 2007 Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 568:213-221
43. Huang KJ, Wang H, Xie WZ, Zhang HS 2007 Investigation of the effect of tanshinone IIA on nitric oxide production in human vascular endothelial cells by fluorescence imaging. Spectrochim Acta A Mol Biomol Spectrosc 68:1180-1186
44. Zhang SZ, Ye ZG, Xia Q, Zhang W, Bruce I 2005 Inhibition of mitochondrial permeability transition pore: a possible mechanism for cardioprotection conferred by pretreatment with Tanshinone IIA. Conf Proc IEEE Eng Med Biol Soc 3:2276-2279
45. Yang L, Zou X, Liang Q, Chen H, Feng J, Yan L, Wang Z, Zhou D, Li S, Yao S, Zheng Z 2007 Sodium tanshinone IIA sulfonate depresses angiotensin II - induced cardiomyocyte hypertrophy through MEK/ERK pathway. Exp Mol Med 39:65-73
46. Yang R, Liu A, Ma X, Li L, Su D, Liu J 2008 Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol 51:396-401
47. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ 2007 Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice. J Clin Invest 117:2791-2801